Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis

Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Baraliakos, X, Braun, J, Laurent, D, Baeten, D, van der Heijde, D, Sieper, J, Emery, P, McInnes, I, van Laar, J, Landewe, R, Wordsworth, P, Wollenhaupt, J, Kellner, H, Wright, A, Vandenhende, F, Radford, K, Borah, B, Hueber, W
التنسيق: Journal article
منشور في: 2013

مواد مشابهة